Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

434

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

ABT-126

Low Dose

DRUG

ABT-126

High Dose

DRUG

placebo

Placebo

Trial Locations (43)

2196

Site Reference ID/Investigator# 67585, Johannesburg

Site Reference ID/Investigator# 67583, Rosebank

6529

Site Reference ID/Investigator# 67584, George

7405

Site Reference ID/Investigator# 67582, Cape Town

7530

Site Reference ID/Investigator# 67586, Belville

10312

Site Reference ID/Investigator# 66525, Staten Island

12462

Site Reference ID/Investigator# 68731, Haidari, Athens

14050

Site Reference ID/Investigator# 68768, Berlin

15123

Site Reference ID/Investigator# 68733, Athens

19053

Site Reference ID/Investigator# 69959, Schwerin

21033

Site Reference ID/Investigator# 71573, Dijon

31059

Site Reference ID/Investigator# 68705, Toulouse

32806

Site Reference ID/Investigator# 66524, Orlando

33407

Site Reference ID/Investigator# 66529, West Palm Beach

33445

Site Reference ID/Investigator# 66522, Delray Beach

33613

Site Reference ID/Investigator# 66531, Tampa

35625

Site Reference ID/Investigator# 68767, Hüttenberg

56403

Site Reference ID/Investigator# 68729, Thessaloniki

60007

Site Reference ID/Investigator# 66526, Elk Grove Village

75013

Site Reference ID/Investigator# 68706, Paris

75475

Site Reference ID/Investigator# 68704, Paris

79106

Site Reference ID/Investigator# 68764, Freiburg im Breisgau

81675

Site Reference ID/Investigator# 68765, Munich

87042

Site Reference ID/Investigator# 77833, Limoges

90806

Site Reference ID/Investigator# 69602, Long Beach

93720

Site Reference ID/Investigator# 66528, Fresno

94109-4841

Site Reference ID/Investigator# 66527, San Francisco

06518

Site Reference ID/Investigator# 66530, Hamden

05201

Site Reference ID/Investigator# 66523, Bennington

J9A 1K7

Site Reference ID/Investigator# 71793, Gatineau

H3T 1E2

Site Reference ID/Investigator# 71794, Montreal

K9H 2P4

Site Reference ID/Investigator# 71798, Peterborough

M3B 2S7

Site Reference ID/Investigator# 71795, Toronto

H4H 1R3

Site Reference ID/Investigator# 71796, Verdun

09648

Site Reference ID/Investigator# 69960, Mittweida

115 21

Site Reference ID/Investigator# 68730, Athens

151 25

Site Reference ID/Investigator# 68732, Athens

570 10

Site Reference ID/Investigator# 68735, Thessaloniki

BA1 3NG

Site Reference ID/Investigator# 67787, Bath

G20 0XA

Site Reference ID/Investigator# 67784, Glasgow

TW8 8DS

Site Reference ID/Investigator# 67786, London

M8 5RB

Site Reference ID/Investigator# 67785, Manchester

WA2 8WA

Site Reference ID/Investigator# 67783, Warrington

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01549834 - Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | Biotech Hunter | Biotech Hunter